Marching ahead with its non-benzodiazepine insomnia drug indiplon, Neurocrine Biosciences Inc. said it priced an offering of 3.75 million shares at $53 per share, for net proceeds of about $200 million. (BioWorld Today)

Regeneron Inc.'s fortunes - and its stock - experienced an upswing Monday with the disclosure of a potential $485 million deal focused on its VEGF Trap product candidate with Aventis SA. (BioWorld Today)

Epimmune Inc. reduced its staff by 23 percent and implemented other cost-cutting measures that the company said would give it enough operating funds to pull results from ongoing clinical trials in HIV and cancer. (BioWorld Today)